24927617|t|Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.
24927617|a|A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir. The patient also received simvastatin. One month after starting the antiviral therapy, the patient was admitted to the hospital because he developed rhabdomyolysis. At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected. The creatine kinase peaked at 62,246 IU/L and the patient was treated with intravenous normal saline. The patient's renal function remained unaffected. Fourteen days after hospitalization, creatine kinase level had returned to 230 IU/L and the patient was discharged. Telaprevir was considered the probable causative agent of an interaction with simvastatin according to the Drug Interaction Probability Scale. The interaction is due to inhibition of CYP3A4-mediated simvastatin clearance. Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood. In conclusion, with this case we illustrate that telaprevir as well as statins are susceptible to clinical relevant drug-drug interactions.
24927617	0	14	Rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
24927617	20	46	hepatitis C virus infected	DiseaseOrPhenotypicFeature	D006526
24927617	47	54	patient	OrganismTaxon	9606
24927617	68	78	telaprevir	ChemicalEntity	C486464
24927617	83	94	simvastatin	ChemicalEntity	D019821
24927617	110	113	man	OrganismTaxon	9606
24927617	129	156	hepatitis C virus infection	DiseaseOrPhenotypicFeature	D006526
24927617	186	195	ribavirin	ChemicalEntity	D012254
24927617	197	217	pegylated interferon	ChemicalEntity	C417083
24927617	222	232	telaprevir	ChemicalEntity	C486464
24927617	238	245	patient	OrganismTaxon	9606
24927617	260	271	simvastatin	ChemicalEntity	D019821
24927617	325	332	patient	OrganismTaxon	9606
24927617	383	397	rhabdomyolysis	DiseaseOrPhenotypicFeature	D012206
24927617	412	423	simvastatin	ChemicalEntity	D019821
24927617	432	447	antiviral drugs	ChemicalEntity	D000998
24927617	474	482	toxicity	DiseaseOrPhenotypicFeature	D064420
24927617	533	548	creatine kinase	ChemicalEntity	D003402
24927617	579	586	patient	OrganismTaxon	9606
24927617	635	642	patient	OrganismTaxon	9606
24927617	718	733	creatine kinase	ChemicalEntity	D003402
24927617	773	780	patient	OrganismTaxon	9606
24927617	797	807	Telaprevir	ChemicalEntity	C486464
24927617	875	886	simvastatin	ChemicalEntity	D019821
24927617	980	986	CYP3A4	GeneOrGeneProduct	1576
24927617	996	1007	simvastatin	ChemicalEntity	D019821
24927617	1019	1030	Simvastatin	ChemicalEntity	D019821
24927617	1079	1086	patient	OrganismTaxon	9606
24927617	1091	1097	statin	ChemicalEntity	D019821
24927617	1106	1121	muscle toxicity	DiseaseOrPhenotypicFeature	D009135
24927617	1161	1167	statin	ChemicalEntity	D019821
24927617	1227	1237	telaprevir	ChemicalEntity	C486464
24927617	1249	1256	statins	ChemicalEntity	D019821
24927617	Negative_Correlation	C417083	D006526	No
24927617	Cotreatment	C417083	C486464	No
24927617	Cotreatment	D012254	C417083	No
24927617	Negative_Correlation	D012254	D006526	No
24927617	Cotreatment	D012254	C486464	No
24927617	Association	1576	D019821	No
24927617	Positive_Correlation	D019821	D009135	Novel
24927617	Drug_Interaction	D019821	D000998	Novel
24927617	Negative_Correlation	D019821	D006526	No
24927617	Positive_Correlation	D019821	D012206	Novel
24927617	Negative_Correlation	C486464	D006526	No
24927617	Drug_Interaction	C486464	D019821	Novel
24927617	Positive_Correlation	C486464	D012206	Novel